{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,5,17]],"date-time":"2024-05-17T21:08:16Z","timestamp":1715980096276},"reference-count":23,"publisher":"Wiley","issue":"1","license":[{"start":{"date-parts":[[2007,2,22]],"date-time":"2007-02-22T00:00:00Z","timestamp":1172102400000},"content-version":"vor","delay-in-days":1513,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Progress Cardiovascular Nurs"],"published-print":{"date-parts":[[2003,1]]},"abstract":"<jats:p> <jats:italic>Despite the development of hypertension treatment guidelines, blood pressure control in the general population remains inadequate, indicating the need for ongoing re\u2010evaluation of treatment strategies to further improve blood pressure control. Hypertension results from alterations in cardiac output and\/or peripheral resistance. The renin\u2010angiotensin\u2010aldosterone system may be responsible, at least in part, for these alterations. Despite pharmacologic intervention with angiotensin\u2010converting enzyme inhibitors and angiotensin type\u20101 receptor antagonists, aldosterone continues to be produced. Therapeutic modalities for treating hypertension directed toward antagonizing aldosterone might more effectively control blood pressure. Eplerenone, a new selective aldosterone receptor antagonist, recently received approval from the US Food and Drug Administration for the treatment of hypertension, either alone or in combination with other antihypertensive agents. The objective of this review is to summarize the renin\u2010angiotensin\u2010aldosterone system, emphasizing the role for aldosterone antagonism in the management of hypertension, with a focus on eplerenone.<\/jats:italic> <\/jats:p>","DOI":"10.1111\/j.0889-7204.2003.01936.x","type":"journal-article","created":{"date-parts":[[2007,2,22]],"date-time":"2007-02-22T13:18:37Z","timestamp":1172150317000},"page":"54-59","source":"Crossref","is-referenced-by-count":0,"title":["Aldosterone Receptor Antagonists: Focus on Eplerenone"],"prefix":"10.1111","volume":"18","author":[{"given":"Robert E.","family":"Lamb","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jon","family":"Folstad","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2007,2,22]]},"reference":[{"key":"e_1_2_7_2_2","doi-asserted-by":"publisher","DOI":"10.1161\/01.HYP.25.3.305"},{"key":"e_1_2_7_3_2","doi-asserted-by":"publisher","DOI":"10.1001\/archinte.1997.00440420033005"},{"key":"e_1_2_7_4_2","first-page":"41","volume-title":"Clinical Hypertension","author":"Kaplan N","year":"1998"},{"key":"e_1_2_7_5_2","doi-asserted-by":"publisher","DOI":"10.1177\/00912709922008155"},{"key":"e_1_2_7_6_2","doi-asserted-by":"publisher","DOI":"10.1159\/000057397"},{"key":"e_1_2_7_7_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF00877755"},{"key":"e_1_2_7_8_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0895-7061(01)02342-1"},{"key":"e_1_2_7_9_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0895-7061(02)02957-6"},{"key":"e_1_2_7_10_2","first-page":"181","volume-title":"Clinical Hypertension","author":"Kaplan N","year":"1998"},{"key":"e_1_2_7_11_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199909023411001"},{"key":"e_1_2_7_12_2","doi-asserted-by":"publisher","DOI":"10.1006\/jmcc.2002.2088"},{"key":"e_1_2_7_13_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.284.4.465"},{"key":"e_1_2_7_14_2","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.304.6824.405"},{"key":"e_1_2_7_15_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM200001203420301"},{"key":"e_1_2_7_16_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(02)08089-3"},{"key":"e_1_2_7_17_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.288.23.2981"},{"key":"e_1_2_7_18_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(98)04311-6"},{"key":"e_1_2_7_19_2","doi-asserted-by":"publisher","DOI":"10.1053\/ajkd.2000.16225"},{"key":"e_1_2_7_20_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1524-6175.2002.02045.x"},{"key":"e_1_2_7_21_2","doi-asserted-by":"publisher","DOI":"10.1161\/01.HYP.0000025146.19104.FE"},{"key":"e_1_2_7_22_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0895-7061(02)02957-6"},{"key":"e_1_2_7_23_2","author":"Pharmacia Corporation","year":"2002","journal-title":"Pharmacia's INSPRA Meets Primary Endpoints in EPHESUS Trial"},{"key":"e_1_2_7_24_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0895-7061(02)02333-6"}],"container-title":["Progress in Cardiovascular Nursing"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.0889-7204.2003.01936.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.0889-7204.2003.01936.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,10]],"date-time":"2023-09-10T17:17:17Z","timestamp":1694366237000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.0889-7204.2003.01936.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2003,1]]},"references-count":23,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2003,1]]}},"alternative-id":["10.1111\/j.0889-7204.2003.01936.x"],"URL":"https:\/\/doi.org\/10.1111\/j.0889-7204.2003.01936.x","archive":["Portico"],"relation":{},"ISSN":["0889-7204","1751-7117"],"issn-type":[{"value":"0889-7204","type":"print"},{"value":"1751-7117","type":"electronic"}],"subject":[],"published":{"date-parts":[[2003,1]]}}}